WO2018143649A1 - 자가 면역 질환의 예방 또는 치료용 약학적 조성물 및 그 제조방법 - Google Patents
자가 면역 질환의 예방 또는 치료용 약학적 조성물 및 그 제조방법 Download PDFInfo
- Publication number
- WO2018143649A1 WO2018143649A1 PCT/KR2018/001294 KR2018001294W WO2018143649A1 WO 2018143649 A1 WO2018143649 A1 WO 2018143649A1 KR 2018001294 W KR2018001294 W KR 2018001294W WO 2018143649 A1 WO2018143649 A1 WO 2018143649A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dendritic cells
- agonist
- toll
- differentiation
- autoimmune diseases
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 54
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 40
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims abstract description 171
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 144
- 238000000034 method Methods 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 230000004069 differentiation Effects 0.000 claims description 153
- 239000003970 toll like receptor agonist Substances 0.000 claims description 124
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims description 94
- 238000011282 treatment Methods 0.000 claims description 84
- 239000000556 agonist Substances 0.000 claims description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 230000001939 inductive effect Effects 0.000 claims description 31
- 206010003246 arthritis Diseases 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 230000002757 inflammatory effect Effects 0.000 claims description 19
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 16
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 16
- 101100481579 Mus musculus Tlr11 gene Proteins 0.000 claims description 10
- 101100481580 Mus musculus Tlr12 gene Proteins 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 8
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims description 8
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 7
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 7
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims description 7
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 7
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims description 7
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims description 7
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 7
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims description 7
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 6
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 6
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 5
- 101100481581 Mus musculus Tlr13 gene Proteins 0.000 claims description 5
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims description 5
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims description 5
- 229940124614 TLR 8 agonist Drugs 0.000 claims description 5
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 3
- 208000006029 Cardiomegaly Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 claims description 3
- 102100032352 Leukemia inhibitory factor Human genes 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010036030 Polyarthritis Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010043781 Thyroiditis chronic Diseases 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 201000009961 allergic asthma Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 claims description 3
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims description 3
- 201000011066 hemangioma Diseases 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 230000010410 reperfusion Effects 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 108700014844 flt3 ligand Proteins 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims 4
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 210000000232 gallbladder Anatomy 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 230000006058 immune tolerance Effects 0.000 abstract description 23
- 230000008569 process Effects 0.000 abstract description 10
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 101100511576 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) lprG gene Proteins 0.000 description 70
- 210000004027 cell Anatomy 0.000 description 45
- 230000014509 gene expression Effects 0.000 description 40
- 210000001744 T-lymphocyte Anatomy 0.000 description 39
- 230000000694 effects Effects 0.000 description 38
- 102000004127 Cytokines Human genes 0.000 description 34
- 108090000695 Cytokines Proteins 0.000 description 34
- 210000003289 regulatory T cell Anatomy 0.000 description 26
- 230000035755 proliferation Effects 0.000 description 24
- 238000010171 animal model Methods 0.000 description 23
- VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 23
- 208000009386 Experimental Arthritis Diseases 0.000 description 22
- 239000000427 antigen Substances 0.000 description 18
- 239000013642 negative control Substances 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 102000002689 Toll-like receptor Human genes 0.000 description 15
- 108020000411 Toll-like receptor Proteins 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 230000028327 secretion Effects 0.000 description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 210000001185 bone marrow Anatomy 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 9
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 8
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 8
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 8
- -1 IL-12p70 Proteins 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 229940100601 interleukin-6 Drugs 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 229960000485 methotrexate Drugs 0.000 description 8
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 7
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 7
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 210000005067 joint tissue Anatomy 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102100026720 Interferon beta Human genes 0.000 description 6
- 108010047761 Interferon-alpha Proteins 0.000 description 6
- 102000006992 Interferon-alpha Human genes 0.000 description 6
- 108090000467 Interferon-beta Proteins 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 238000007898 magnetic cell sorting Methods 0.000 description 6
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 6
- 239000000344 soap Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 description 5
- 102000008096 B7-H1 Antigen Human genes 0.000 description 5
- 102000008070 Interferon-gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 102000043131 MHC class II family Human genes 0.000 description 5
- 108091054438 MHC class II family Proteins 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000003162 effector t lymphocyte Anatomy 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229960003130 interferon gamma Drugs 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000013691 Interleukin-17 Human genes 0.000 description 4
- 108050003558 Interleukin-17 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000000475 sunscreen effect Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 3
- 102000002227 Interferon Type I Human genes 0.000 description 3
- 108010014726 Interferon Type I Proteins 0.000 description 3
- 108010028921 Lipopeptides Proteins 0.000 description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 3
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- UPAQRWMRKQCLSD-HTIIIDOHSA-N 2,3-dipalmitoyl-S-glycerylcysteine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CSC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC UPAQRWMRKQCLSD-HTIIIDOHSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010040721 Flagellin Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 101150053046 MYD88 gene Proteins 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 description 2
- 241001111421 Pannus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 108010038122 S-(2,3-bis(palmitoyloxy)propyl)cysteine Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 241000223997 Toxoplasma gondii Species 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004544 dc2 Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 201000008752 progressive muscular atrophy Diseases 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229950010550 resiquimod Drugs 0.000 description 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000003614 tolerogenic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- OWMCODAXNFNLCU-UHFFFAOYSA-N 2-[[2-(1h-imidazol-5-yl)ethylamino]methyl]phenol Chemical compound OC1=CC=CC=C1CNCCC1=CN=CN1 OWMCODAXNFNLCU-UHFFFAOYSA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001553290 Euphorbia antisyphilitica Species 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010009489 Lysosomal-Associated Membrane Protein 3 Proteins 0.000 description 1
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 description 1
- 241000710118 Maize chlorotic mottle virus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 101000897464 Mus musculus C-C motif chemokine 2 Proteins 0.000 description 1
- 101100327190 Mus musculus Ccl5 gene Proteins 0.000 description 1
- 101000819572 Mus musculus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 101001033286 Mus musculus Interleukin-1 beta Proteins 0.000 description 1
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
- 101100018084 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) htpG gene Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100027009 Toll-like receptor 10 Human genes 0.000 description 1
- 102000008228 Toll-like receptor 2 Human genes 0.000 description 1
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940060265 aldara Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 description 1
- 229910000422 cerium(IV) oxide Inorganic materials 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 241001492478 dsDNA viruses, no RNA stage Species 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 108010080417 hemozoin Proteins 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 102000054350 human CHI3L1 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 229940124669 imidazoquinoline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006057 immunotolerant effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000010656 jasmine oil Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 244000145841 kine Species 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229950005634 loxoribine Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical group C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 206010035485 plasmacytosis Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000013183 regulation of T cell differentiation Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- DQJCHOQLCLEDLL-UHFFFAOYSA-N tricyclazole Chemical compound CC1=CC=CC2=C1N1C=NN=C1S2 DQJCHOQLCLEDLL-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Definitions
- the present invention relates to a method for preparing a composition capable of preventing, ameliorating or treating an autoimmune disease and to a composition prepared by the method.
- the immune response and immune tolerance response must be balanced and balanced. Hyper-immune reactions can lead to irritable allergic diseases and autoimmune diseases, which have a great impact on human survival and quality of life.
- autoimmune diseases are diseases that appear as an adverse reaction to autologous cells.
- therapeutic agents are most commonly used immunosuppressants that block signal transduction pathways in T cells, but these immunosuppressive agents are toxic, infection, lymphoma, diabetes, Side effects such as tremor, headache, diarrhea, high blood pressure, nausea, renal dysfunction, etc. occur. Therefore, there is a need for the development of a new therapeutic agent having no side effects and inexpensive and excellent therapeutic effect.
- rheumatoid arthritis which is a type of autoimmune disease, is the most commonly occurring inflammatory arthritis in adults, and its cause is not yet fully known, but it is understood as an inflammatory response due to an autoimmune mechanism.
- antirheumatic drugs and biological agents used to treat rheumatoid arthritis have been shown to improve quality of life through symptom control, they are still insufficient to prevent disorders through the reduction of cartilage and bone destruction, the ultimate therapeutic target.
- the therapeutic effect is incomplete, antibodies are produced when the biological agent is used for a long time, and the therapeutic effect is decreased, and many drug side effects are hindering treatment.
- Dendritic cells play a pivotal role in regulating acquired immunity, which is selectively generated by acquired causality as well as innate immunity. It is a kind of representative antigen presenting cells to perform.
- the dendritic cells are composed of various subpopulations according to origin, phenotype, function, and the like. Specifically, plasmacytoide dendritic cells (pDC) can produce high levels of type I IFN in response to various pathogen-derived stimuli. They are distinguished from conventional dendritic cells (cDCs) by surface phenotype. The pDC expresses B220 and CD11c expresses low levels, while cDC expresses high levels of CD11c and CD11b, but does not express B220. Both pDCs and cDCs are obtained by the process of maturation of immature dendritic cells so that they can act as effective stimulators of a harmonious immune response.
- pDCs are known to play an important role in the defense of viral infections by activating immune cells by releasing large amounts of type I IFNs when infected by DNA viruses or single-stranded RNA viruses.
- mDCs mature DCs
- the inventors of the present invention treated toll-like receptor agonists (TLR agonists) in immature dendritic cells and then induced differentiation, or toll-like receptor agonists during the process of differentiating immature dendritic cells.
- TLR agonists toll-like receptor agonists
- the immune tolerant plasmacytoid dendritic cells are induced, and when used, the present inventors have found that the autoimmune disease can be effectively prevented, improved or treated.
- One object of the present invention is to provide a method for preparing a composition that can effectively prevent, ameliorate or treat autoimmune diseases.
- Another object of the present invention is to provide a composition prepared by the above method, which can effectively prevent, ameliorate or treat autoimmune diseases.
- the present invention comprises the step of treating toll-like receptor agonist to immature dendritic cells to produce immune tolerant plasmacytoid dendritic cells (pDC),
- pDC plasmacytoid dendritic cells
- the present invention also provides a pharmaceutical composition for preventing or treating autoimmune diseases, including immune tolerant plasmacytoid dendritic cells induced by treating toll-like receptor agonists to immature dendritic cells.
- the present invention also provides a cosmetic composition for preventing or ameliorating autoimmune diseases, including immune tolerant plasmacytoid dendritic cells induced by treating a toll-like receptor agonist to immature dendritic cells.
- the present invention also provides a food composition for preventing or ameliorating autoimmune diseases, including immune tolerant plasmacytoid dendritic cells induced by treating toll-like receptor agonists to immature dendritic cells.
- the present invention can induce high yield of plasmacytoid dendritic cells having immune tolerance from immature dendritic cells through a simple and easy process, thereby enabling a stable supply of large amounts of immune tolerant plasmacytoid dendritic cells.
- the immune tolerant plasmacytoid dendritic cells obtained as described above in the present invention can effectively prevent or treat various autoimmune diseases by inhibiting the expression of inflammatory cytokines and inflammation causing factors, and are safe when administered to a human body.
- Figure 1 shows the design of the method for treating differentiation-inducing factors (Flt3L-containing media) and toll-like receptor agonists (TLR agonists) for immature dendritic cells according to an embodiment of the present invention.
- differentiation-inducing factors Flt3L-containing media
- TLR agonists toll-like receptor agonists
- FIG. 2 shows the separation of differentiation-induced plasmacytoid dendritic cells (TLRs-pDC) after treatment of toll-like receptor agonist (Pam3) in Example 1 according to one embodiment of the present invention.
- FIG. 3 (a) shows surface expression molecules specifically induced in differentiation-induced plasmacytoid dendritic cells after treatment of toll-like receptor agonist (Pam3) in Example 1 according to one embodiment of the present invention.
- Figure 3 (b) is a graph of the ratio of the number of immature dendritic cells in Example 1 compared to the number of differentiation-induced plasma cytokine dendritic cells after treatment of toll-like receptor agonist (Pam3) according to an embodiment of the present invention It is shown.
- FIG. 4 shows cytokines in differentiation-induced plasmacytoid dendritic cells (TLRs-pDC) and common plasmacytoid dendritic cells (pDC) after treatment of toll-like receptor agonist (Pam3) in Example 2 according to one embodiment of the present invention.
- TLRs-pDC differentiation-induced plasmacytoid dendritic cells
- pDC common plasmacytoid dendritic cells
- IFN- ⁇ , IFN- ⁇ , IL-12p70, IL-10 toll-like receptor agonist
- Figure 5 shows the expression patterns of cytokine IL-10 in differentiation-induced plasmacytoid dendritic cells and general plasmacytoid dendritic cells (non) after treatment of various toll-like receptor agonists according to an embodiment of the present invention in Example 3
- the graph shows the result of comparing.
- FIG. 6 shows cytokines (IFN- ⁇ , IFN- ⁇ , TNF- ⁇ , IL) according to the time point of treatment of toll-like receptor agonist (Pam3) treated to immature dendritic cells according to an embodiment of the present invention in Example 4. -12p70, IL-10) is shown in a graph comparing the expression pattern.
- TLRs-pDC differentiation-induced plasmacytoid dendritic cells
- pDC general plasmacytoid dendritic cells
- the graph shows the results of comparing the expression patterns of the complex molecules, CD80 and CD86.
- FIG. 8 shows IDO in differentiation-induced plasmacytoid dendritic cells (TLRs-pDC) and common plasmacytoid dendritic cells (pDC) after treatment of toll-like receptor agonist (Pam3) in Example 6.
- TLRs-pDC differentiation-induced plasmacytoid dendritic cells
- pDC common plasmacytoid dendritic cells
- Pam3 toll-like receptor agonist
- TLRs-pDC plasmacytoid dendritic cells
- Pam3 toll-like receptor agonist
- FIG. 9 (b) shows the differentiation-induced differentiation of plasmacytoid dendritic cells (TLRs-pDC) or general plasmacytosis after treatment of toll-like receptor agonist (Pam3) according to one embodiment of the present invention.
- TLRs-pDC plasmacytoid dendritic cells
- Pam3 toll-like receptor agonist
- FIG 10 shows the degree of binding of Rv1411c protein of dendritic cells (TLR2-/-) isolated from wild-type dendritic cells (WT) and TLR2 knockout mice in Example 8.
- FIG. 11 shows the differentiation-induced plasmacytoid dendritic cells (Rv1411c (0.1 ⁇ g) after treatment of toll-like receptor agonists (Rv1411c protein (0.1 ⁇ g / ml, 0.5 ⁇ g / ml)) according to an embodiment of the present invention in Example 9. / ml) -pDC, Rv1411c (0.5 ⁇ g / ml) -pDC) and cytokines (IFN- ⁇ , IFN- ⁇ , TNF- ⁇ , IL-12p70, IL-10) in common plasmacytoid dendritic cells (pDC) The graph shows the results of comparing the expression patterns.
- Example 10 shows in Example 10 differentiation-induced plasmacytoid dendritic cells (Rv1411c-pDC) and general plasmacytoid dendritic cells (pDC) after treatment of toll-like receptor agonists (Rv1411c protein) according to one embodiment of the present invention.
- Comparison of the expression patterns of MHC complex molecules, CD80, CD86 and immune tolerance induction molecules (IDO, CCR9 and PD-L1) is shown graphically.
- Figure 13 shows the differentiation-induced plasmacytoid dendritic cells (Rv1411c-pDC) or general plasmacytoid dendritic cells after treatment of T cells in Example 11 and toll-like receptor agonist (Rv1411c protein) according to one embodiment of the present invention.
- pDC is a graph showing the results of comparing the degree of proliferation of T cells after the mixed culture.
- Figure 14 shows the differentiation-induced plasmacytoid dendritic cells (Rv1411c-pDC) or common plasmacytoid dendritic cells after treatment of T cells in Example 11 and toll-like receptor agonist (Rv1411c protein) according to one embodiment of the present invention. (pDC) after the mixed culture and confirmed the secretion pattern of IFN-gamma is shown in the graph.
- FIG. 15 (a) shows differentiation-induced plasmacytoid dendritic cells (Rv1411c-pDC) or general plasma after treatment of toll-like receptor agonist (Rv1411c protein) according to an embodiment of the present invention with respect to T cells in Example 12.
- pDC cytokine dendritic cells
- FIG. 15B shows differentiation-induced plasmacytoid dendritic cells (RVc1411c-pDC) or general plasma after treatment of Toll-like receptor agonist (Rv1411c protein) according to an embodiment of the present invention with respect to T cells in Example 12.
- the result of measuring the proliferation rate of regulatory T cells after treatment with cytoid dendritic cells (pDC) is shown graphically.
- FIG. 16 shows a toll-like receptor agonist (Rv1411c protein) according to one embodiment of the present invention in Example 13.
- T cells differentiated by plasmacytoid dendritic cells (RVc1411c-pDC) induced after treatment were incubated with CD4 + and CD25-acting T cells, and then T cells to the ratio of primed T cells to CD25-acting T cells.
- the graph shows the results of measuring changes in proliferative capacity.
- TLR agonist plasma cytokine dendritic cells
- Non plasma cytokine dendritic cells
- Example 18 shows an experimental design for preparing a collagen-induced arthritis animal model in Example 15.
- FIG. 19 is a negative control group with differentiation-induced plasmacytoid dendritic cells (TLRs-tolpDC) after treatment of toll-like receptor agonist (Rv1411c protein) according to an embodiment of the present invention in a collagen-induced arthritis animal model mouse in Example 15.
- TLRs-tolpDC differentiation-induced plasmacytoid dendritic cells
- Rv1411c protein toll-like receptor agonist
- FIG. Phosphorylated Buffer Aqueous Solution (PBS), a positive control, treated with the common plasmacytoid dendritic cells (pDC) and metrotrexate (MTX) after the evaluation of arthritis scores are shown graphically.
- FIG. 20 is a negative control group with differentiation-induced plasmacytoid dendritic cells (TLRs-tolpDC) after treatment of a toll-like receptor agonist (Rv1411c protein) according to an embodiment of the present invention in a collagen-induced arthritis animal model mouse in Example 15 Phosphorylated buffered aqueous solution (PBS) and a positive control were treated with general plasma cytoplasmic dendritic cells (pDC) and metrotrexate (MTX).
- PBS Phosphorylated buffered aqueous solution
- pDC general plasma cytoplasmic dendritic cells
- MTX metrotrexate
- FIG. 21 is a negative control group with differentiation-induced plasmacytoid dendritic cells (TLRs-pDC) after treatment of toll-like receptor agonist (Rv1411c protein) according to an embodiment of the present invention in a collagen-induced arthritis animal model mouse in Example 16.
- TLRs-pDC differentiation-induced plasmacytoid dendritic cells
- Rv1411c protein toll-like receptor agonist
- FIG. 22 is a negative control group with differentiation-induced plasmacytoid dendritic cells (TLRs-pDC) after treatment of toll-like receptor agonist (Rv1411c protein) according to one embodiment of the present invention in a collagen-induced arthritis animal model mouse in Example 16.
- TLRs-pDC differentiation-induced plasmacytoid dendritic cells
- Rv1411c protein toll-like receptor agonist
- FIG. 23 is a negative control group with differentiation-induced plasmacytoid dendritic cells (TLRs-pDC) after treatment of a toll-like receptor agonist (Rv1411c protein) according to an embodiment of the present invention in a collagen-induced arthritis animal model mouse in Example 17.
- PBS Phosphorylated buffered aqueous solution
- MTX metrotrexate
- TNF- ⁇ tumor necrosis factor- ⁇
- IL-6 interleukin-6
- IL-17 interleukin-17
- FIG. 24 is a negative control group with differentiation-induced plasmacytoid dendritic cells (TLRs-pDC) after treatment of toll-like receptor agonist (Rv1411c protein) according to an embodiment of the present invention in a collagen-induced arthritis animal model mouse in Example 18.
- TLRs-pDC differentiation-induced plasmacytoid dendritic cells
- Rv1411c protein toll-like receptor agonist
- the present invention relates to a method for preparing a pharmaceutical composition for preventing or treating autoimmune diseases, including the steps of preparing the following immune tolerant plasmacytoid dendritic cells.
- the step of preparing the immune tolerant plasmacytoid dendritic cells may be performed by treating toll-like receptor agonists to immature dendritic cells.
- DC dendritic cell
- MHC major histocompatibility complex
- mDC mature dendritic cells
- the term “immature dendritic cell” is found in the early stages of maturation of dendritic cells and does not express CD14, the surface phenotype of monocyte cells, and also does not include any of the co-stimulatory molecules CD40, CD54, CD80, CD86 and CD274. One is expressed at low levels compared to mature dendritic cells.
- the term “quasi-dendritic dendritic cell” is a dendritic cell that loses some of the properties of immature dendritic cells and has some characteristics of the phenotype of mature dendritic cells, and partially or incompletely matured morphological and phenotypic characteristics. Meaning dendritic cells.
- mature dendritic cell refers to a cell formed by maturation of immature dendritic cells.
- Mature dendritic cells have high expression of MHC class II, CD40, CD54, CD80, CD86, and CD274 as well as DC-LAMP, release anti-inflammatory cytokine, and primitive allogeneic in mixed lymphocyte reactions. Characterized by having the ability to produce increased production of allogeneic T cells and syngeneic T cells and / or increased production of dendritic cell cytokines.
- Mature dendritic cells typically express high levels of CCR7 and CXCR4.
- the dendritic cells to which the toll-like receptor agonist is treated are preferably immature dendritic cells that are not differentiated.
- the immature dendritic cells may include primitive dendritic cells, and may be isolated and obtained from mammalian bone marrow or the like.
- the immune tolerant dendritic cells induced by differentiation by treating toll-like receptor agonists to immature dendritic cells as described above may be immune tolerant plasmacytoid dendritic cells (pDC).
- pDC plasmacytoid dendritic cells
- plasmacytoid dendritic cells refers to a subset of dendritic cells, 1958, Lennert and Dr. Plasmacytoid T cells, first known by histological detection of plasma cell morphology in human lymph nodes, but not expressing B cell specific markers (Plasmacytoid T cells) After being known to express myeloid lineage antigen and MHC class II without expressing CD3, a common marker of T cells, it was named plasmacyytoid monocyte. After that, the ability to induce an allerogenic mixed lymphocyte reaction (MLR), which is inherent in dendritic cells, has been identified, which is again referred to as plasmacytoid dendritic cells, or simply referred to as 'pDC'. do.
- MLR mixed lymphocyte reaction
- the term “immune tolerance” refers to a state that suppresses an immune response as well as a state that does not exhibit an immune response to a specific antigen. Therefore, in the present invention, the "immune tolerant plasmacytoid dendritic cells” promote the secretion of anti-inflammatory cytokines such as IL-10, inhibit the secretion of inflammatory cytokines such as IL-12p70 and TNF- ⁇ , Indoleamine-2,3 dioxygenase (IDO) molecules, recently known as immune tolerance inducing molecules, and CCR9, a surface molecule of immune tolerance induction cells, are expressed at high levels. Induce differentiation of regulatory T cells and inhibit the activity of effector T cells.
- anti-inflammatory cytokines such as IL-10
- IDO Indoleamine-2,3 dioxygenase
- immune tolerant plasmacytoid dendritic cells can be stably and in large quantities prepared by treating the toll-like receptor agonist before or during differentiation of immature dendritic cells.
- the term "before the differentiation start” may include a time point before the immature dendritic cells are treated with a factor for inducing differentiation.
- the term “differentiating” means a time point from the time of processing the factor for inducing differentiation to the immature dendritic cells until the differentiation is completed by the factor for inducing differentiation. Preferably, it may include a time within 7 days after the treatment from the time of processing the factor for inducing differentiation, but is not limited thereto.
- the toll-like receptor agonist is not particularly limited as long as it is treated only before or during the differentiation of immature dendritic cells as described above.
- the toll-like receptor agonist may be treated within 7 days (168 hours), 5 days (120 hours) or 3 days (72 hours) from the start of differentiation.
- the present invention is not limited thereto.
- the immature dendritic cells may be depleted by using a factor for inducing differentiation within 36 hours, preferably 24 hours, after the agent is treated. Differentiation may be initiated, but is not limited thereto.
- the toll-like receptor agonist may be treated one or more times, and the number of specific treatments is not particularly limited, but when the toll-like receptor agonist is treated during differentiation of immature dendritic cells, the immature dendritic cells are differentiated.
- the toll like receptor agonist may be treated at least once within 7, 5 or 3 days from the start.
- the immature dendritic cell is treated at least once with the toll-like receptor agonist, and then within 36 hours or 24 hours from any one treatment time point. Differentiation of immature dendritic cells may be initiated and optionally further treated one or more times during the differentiation.
- the "initiation of differentiation” may mean a process of adding a factor for inducing differentiation to a culture medium of immature dendritic cells or inoculating immature dendritic cells in a medium containing a factor for inducing differentiation.
- the differentiation-inducing factor is not particularly limited as long as it can induce differentiation of immature dendritic cells.
- the term "toll-like receptor agonist” is a pathogen-derived conserved molecular substance, which may be Pathogen associated molecular patterns (PAMPs).
- PAMPs Pathogen associated molecular patterns
- the pathogen may be Gram-positive bacterium, Gram-negative bacterium, fungus or virus.
- the toll-like receptor agonists are endogenous molecules released from damaged or dead cells, and may be Damage associated molecular patterns (DAMPs). DAMPs or PAMPs collect adapter molecules in the cytoplasm of the cell to initiate and transmit an immune response via the TLR signal.
- the toll like receptor agonist will be a derivative of PAMPs or DAMPs that bind to fragments, variants, analogs, homology or toll like receptors and induce activation by TLR-mediated, such as activation of NF- ⁇ B activity.
- TLR-mediated such as activation of NF- ⁇ B activity.
- the toll-like receptor agonist fragments, variants, analogs, homologs or derivatives are at least 30-99% identical to the amino acids of the TLR agonist and will induce activation by toll-like receptor-mediated.
- the type of toll-like receptor agonist to be treated to the immature dendritic cells is not particularly limited, but is preferably a PAMP ligand, more preferably immature that can pass through MyD88 (Myeloid differentiation primary response gene 88) signal. Differentiation of immune tolerant plasmacytoid dendritic cells can be induced from dendritic cells.
- the toll-like receptor agonist in the present invention may include one or more selected from the group consisting of TLR2 agonist, TLR4 agonist, TLR5 agonist, TLR7 agonist, TLR8 agonist, TLR9 agonist, TLR11 agonist, TLR12 agonist and TLR13 agonist.
- TLR2 agonist TLR4 agonist
- TLR5 agonist TLR5 agonist
- TLR7 agonist TLR8 agonist
- TLR9 agonist TLR11 agonist
- TLR12 agonist and TLR13 agonist TLR13 agonist.
- one or more of the ligands shown in Table 1 may be included, but is not particularly limited thereto, and may bind to toll-like receptors of dendritic cells, and may be a ligand that may pass through a MyD88 signal. Can be used without limitation.
- the TLR2 agonist when used as the toll-like receptor agonist in the present invention, it may further include at least one of a TLR1 agonist and a TLR6 agonist that acts as a co-receptor.
- a TLR1 agonist and a TLR6 agonist that acts as a co-receptor.
- specific examples of the TLR1 agonist and the TLR6 agonist may be ligands shown in Table 1 below, but any ligand that may act as a co-receptor of the TLR2 agonist is not particularly limited.
- Ligand Pathogen Associated Ligands Ligand-derived host Synthetic ligands TLR1 Multiple triacyl lipopeptides bacteria Pam3Cys- * TLR2 Multiple Glycolipids bacteria CFA Multiple lipopeptides bacteria Pam3, MALP2-** Multiple lipoproteins bacteria Pam2Cys ** Lipoteichoic acid Gram-positive bacteria FSL-1 HSP 70, or other heat shock proteins Host cells Hib-OMPC Zymosan (Beta-glucan) Fungi protein Mycobacterium tuberculosis Rv1411c Protein, ESAT-6, PE / PPE Protein, Rv0577 TLR3 Double stranded RNA virus Poly (I: C); Low or High Molecular Weight Poly (A: U) TLR4 Lipopolysaccharides (LPS); or IPS analogue (MPLA) Gram negative bacteria AGP Heat shock protein Bacteria and Host Cells MPLA Fibrinogen Host cell RC-529 Heparin sulfate
- TLR10 TLR11
- Profili Toxoplasma gondii TLR12
- Profili Toxoplasma gondii TLR13
- the toll-like receptor agonist may be derived from a microorganism, a virus, a plant or an animal, may be synthesized, and the source is not particularly limited.
- the differentiation of the immature dendritic cells in the present invention can be performed using a factor for inducing differentiation.
- a factor for inducing differentiation it is preferable to use FMS-like tyrosine kinase 3 ligand (FMS-like tyrosine kinase 3, Flt3L).
- the immature dendritic cells may be plasmacytoid dendritic cells and general dendritic cells (conventional). There is no particular restriction as long as it can induce differentiation into plasmacytoid cells (cDC).
- the differentiation of the immature dendritic cells in the present invention may be performed by culturing the immature dendritic cells in a medium containing a factor for inducing differentiation, or by adding the factor for inducing differentiation to the culture medium of the immature dendritic cells.
- the factor for inducing differentiation may be additionally added one or more times during the process of differentiating the immature dendritic cells.
- FMS-like tyrosine kinase 3 (Flt3L) corresponds to endogenous small molecules that activate hematopoietic progenitors to perform cytokines and growth factors. do.
- the differentiation period of the immature dendritic cells in the present invention is not particularly limited, and may vary depending on the type and environment of the medium used, for example, may be performed for 5 to 15 days, preferably 7 days May be carried out for 10 to 10 days, more preferably for 8 to 9 days.
- the immune tolerance of the plasmacytoid dendritic cells can be activated.
- the kind of toll-like receptors used for activating the differentiated immune tolerant plasmacytoid dendritic cells as described above is not particularly limited, and the TLR1 agonist, TLR2 agonist, TLR3 agonist, TLR4 agonist, TLR5 agonist, TLR6 agonist It may include one or more selected from the group consisting of, TLR7 agonist, TLR8 agonist, TLR9 agonist, TLR11 agonist, TLR12 agonist and TLR13 agonist, but preferably TLR9 agonist may be used.
- the above-described process can effectively induce differentiation from immature dendritic cells to immune tolerant plasmacytoid dendritic cells. Accordingly, immature dendritic cells can be used to stably supply a large amount of immune tolerant plasmacytoid dendritic cells through a simple and easy process.
- the immune tolerant plasmacytoid dendritic cells obtained as described above in the present invention inhibit the expression of inflammatory cytokines, promote the expression of anti-inflammatory cytokines, induce differentiation into regulatory T cells and operate By suppressing the activity of effector T cells to effectively suppress the immune response, various autoimmune diseases can be effectively prevented or treated, and recurrence by the same antigen can be suppressed.
- autoimmune disease in the present invention is a non-malignant disease or disorder that occurs and is directed against an individual's own tissue.
- One of the most important traits of all normal individuals is that they do not deleteriously react with the antigenic substances that make up self, while non-self antigens can be recognized and reacted to eliminate them.
- Biological nonresponsiveness to self antigens is referred to as immunologic unresponsiveness or tolerance.
- an abnormality occurs in inducing or maintaining self-tolerance
- an immune response occurs to self antigens, and as a result, an attack on one's own tissue occurs.
- the disease caused by this process is called an autoimmune disease.
- the autoimmune disease is an inflammatory disease in which antibodies are produced against its own organ tissues or components thereof, and may refer to diseases causing chronic systemic inflammation in many tissues and organs.
- the autoimmune disease in the present invention is rheumatoid arthritis, systemic lupus erythematosus, sepsis shock, allergic asthma, allergic rhinitis, atopic dermatitis, ulcerative colitis, lacrimitis, Alzheimer's disease, stroke, arteriosclerosis, blood vessels Restenosis, type I diabetes, type II diabetes, gall margin, conjunctivitis, psoriasis, systemic inflammatory syndrome, multiple myositis, dermatitis, nodular polyarthritis, mixed connective histosis, Sjogren's syndrome, gout, Parkinson's disease, muscular dystrophy , Diabetic retinopathy, multiple sclerosis, Crohn's disease, chronic thyroiditis, ceria disease, myasthenia gravis, vulgaris ulcer, viral disease, bacterial disease, radiation disorders, arteriosclerosis, hemangiomas, angiofibromas, reperfusion disorders and cardiac hypertrophy At least one selected from the group consist
- prevention means any action that inhibits or delays the progression of autoimmune disease by administration of the composition of the present invention.
- Treatment and “improvement” in the present invention means all the actions that improve or beneficially change the symptoms of the autoimmune disease by administration of the composition of the present invention.
- the pharmaceutical composition may be characterized in the form of capsules, tablets, granules, injections, ointments, powders or beverages, the pharmaceutical composition may be characterized in that it is intended for humans.
- compositions of the present invention are not limited to these, but each may be formulated in the form of oral dosage forms, such as powders, granules, capsules, tablets, aqueous suspensions, external preparations, suppositories, and sterile injectable solutions according to conventional methods.
- the pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers can be used as oral administration binders, suspending agents, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, pigments, fragrances, etc.
- buffers, preservatives, analgesic Topical agents, solubilizers, isotonic agents, stabilizers and the like can be mixed and used, and for topical administration, bases, excipients, lubricants, preservatives and the like can be used.
- the formulation of the pharmaceutical composition of the present invention can be prepared in various ways by mixing with the pharmaceutically acceptable carrier as described above.
- oral administration may be in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like, in the case of injections, in unit dosage ampoules or multiple dosage forms. have. And others, solutions, suspensions, tablets, capsules, sustained release preparations and the like.
- Suitable carriers, excipients, and diluents for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like can be used.
- fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives and the like may be further included.
- Routes of administration of the pharmaceutical compositions according to the invention are not limited to these, but are oral, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical , Sublingual or rectal. Oral or parenteral release is preferred.
- parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intramuscular, intrasternal, intradural, intralesional and intracranial injection or infusion techniques.
- the pharmaceutical compositions of the invention may also be administered in the form of suppositories for rectal administration.
- the pharmaceutical compositions of the present invention depend on a number of factors, including the activity, age, weight, general health, sex, formulation, time of administration, route of administration, rate of release, drug combination and severity of the particular disease to be prevented or treated, of the specific compound employed. It may vary and the dosage of the pharmaceutical composition depends on the condition, weight, extent of disease, drug form, route of administration and duration of the patient, but may be appropriately selected by those skilled in the art, 0.0001 to 50 mg / day It may be administered at kg or 0.001 to 50 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
- the pharmaceutical composition according to the present invention may be formulated as pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions.
- composition of the present invention can be used alone or in combination with a conventional autoimmune disease agent, for example, in combination with methotrexate (MTX), a therapeutic agent for rheumatoid arthritis, or surgery, radiation therapy, hormone therapy, chemotherapy and biological reactions. It can be used in combination with methods using a modulator.
- MTX methotrexate
- a therapeutic agent for rheumatoid arthritis or surgery, radiation therapy, hormone therapy, chemotherapy and biological reactions. It can be used in combination with methods using a modulator.
- the present invention also relates to a method of treating an autoimmune disease comprising administering a pharmaceutically effective amount of the pharmaceutical composition according to the present invention to an individual suffering from an autoimmune disease.
- the present invention also relates to a method for preventing autoimmune disease comprising administering a pharmaceutically effective amount of the pharmaceutical composition according to the present invention to an individual suffering from autoimmune disease.
- compositions administered in the therapeutic or prophylactic methods of the present invention overlap with those described above, and the following description is omitted to avoid excessive complexity of the description.
- the method of administering the pharmaceutical composition may be administered orally or parenterally, and in parenteral administration, intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, intrauterine dural injection, cerebrovascular It can be administered by intracerebroventricular injection or intrathoracic injection.
- the composition can be administered orally during clinical administration and can be used in the form of a general pharmaceutical formulation.
- the number of administration of the pharmaceutical composition is not particularly limited, and may be performed one or more times, and more specifically, may be repeated administration of one or more times or symptoms depending on the purpose of prevention and treatment, but preferably Can be administered once to three times.
- the pharmaceutically effective amount is 0.0001 to 50 mg / kg or 0.001 to 50 mg / kg, but is not limited thereto.
- the dosage may vary depending on the weight, age, sex, health condition, diet, duration of administration, method of administration, clearance, severity of the disease, and the like of the particular patient.
- the term "administration" means providing a subject of any composition of the invention in any suitable manner.
- the term "individual” means all animals, such as humans, monkeys, dogs, goats, pigs, or rats, having a disease in which autoimmune diseases can be improved by administering the composition of the present invention.
- the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit or risk ratio applicable to medical treatment, which is dependent on the type of disease, the severity, the activity of the drug, the drug, and the drug. Sensitivity, time of administration, route of administration and rate of release, duration of treatment, factors including drug used concurrently, and other factors well known in the medical arts.
- the present invention also relates to a method for preparing a cosmetic composition for preventing or improving autoimmune disease, comprising the step of preparing the above-mentioned immune tolerant plasma cytoplasmic dendritic cells.
- the cosmetic composition is a lotion, nutrition lotion, nutrition essence, massage cream, beauty bath additives, body lotion, body milk, bath oil, baby oil, baby powder, shower gel, shower cream, sunscreen lotion, sunscreen cream, Suntan cream, skin lotion, skin cream, sunscreen cosmetic, cleansing milk, depilatory ⁇ cosmetic ⁇ , face and body lotion, face and body cream, skin whitening cream, hand lotion, hair lotion, cosmetic cream, jasmine oil, Bath Soap, Water Soap, Beauty Soap, Shampoo, Hand Cleanser (Hand Cleaner), Medicated Soap ⁇ Non-Medical ⁇ , Cream Soap, Facial Wash, Systemic Cleanser, Scalp Cleaner, Hairrin, Cosmetic Soap, Tooth Whitening Gel, Toothpaste It may be prepared in the form.
- the composition of the present invention may further comprise a solvent or a suitable carrier, excipient or diluent commonly used in the preparation of the cosmetic composition.
- the kind of the solvent that can be further added in the cosmetic composition of the present invention is not particularly limited, but, for example, water, saline, DMSO, or a combination thereof may be used, and as the carrier, excipient or diluent, purified water, oil, wax , Fatty acids, fatty acid alcohols, fatty acid esters, surfactants, humectants, thickeners, antioxidants, viscosity stabilizers, chelating agents, buffers, lower alcohols, and the like.
- a whitening agent, a moisturizing agent, vitamins, sunscreens, perfumes, dyes, antibiotics, antibacterial agents, antifungal agents may be included as necessary.
- the oil may be hydrogenated vegetable oil, castor oil, cottonseed oil, olive oil, palm oil, jojoba oil, avocado oil, wax, wax, carnauba, candelilla, montan, ceresin, liquid paraffin, lanolin Can be used.
- Stearic acid, linoleic acid, linolenic acid, oleic acid may be used as fatty acids, cetyl alcohol, octyl dodecanol, oleyl alcohol, pantenol, lanolin alcohol, stearyl alcohol, hexadecanol may be used as fatty acid alcohol.
- Isopropyl myristate, isopropyl palmitate, butyl stearate may be used as the fatty acid ester.
- surfactants cationic surfactants, anionic surfactants and nonionic surfactants known in the art can be used, and surfactants derived from natural products are preferred as much as possible.
- it may include a hygroscopic agent, a thickener, an antioxidant, and the like, which are widely known in the cosmetic field, and their types and amounts are known in the art.
- the present invention also relates to a method for preparing a food composition for preventing or improving autoimmune disease, comprising the step of preparing the above immune tolerant plasmacytoid dendritic cells.
- the food composition of the present invention may be prepared in the form of various foods, for example, beverages, gums, teas, vitamin complexes, powders, granules, tablets, capsules, sweets, rice cakes, breads and the like. Since the food composition of the present invention is composed of plant extracts having little toxicity and no side effects, it can be used with confidence even for long-term use for prophylactic purposes.
- the amount may be added at a ratio of 0.1 to 50% of the total weight.
- natural carbohydrates include monosaccharides such as glucose, disaccharides such as fructose, sucrose and the like, and common sugars such as polysaccharides, dextrins and cyclodextrins, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- the flavourant include natural flavourants (tautin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.), synthetic flavors (saccharin, aspartame, etc.).
- compositions of the present invention include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners. , pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like.
- additives can be used independently or in combination.
- the proportion of such additives is not so critical but is usually selected in the range of 0.1 to about 50 parts by weight per 100 parts by weight of the composition of the present invention.
- femoral bone marrow was collected from bone marrow harvesting injections from C57BL / 6 mice.
- the collected bone marrow was washed with phosphate buffer saline (PBS) and red blood cells were removed using ammonium chloride.
- PBS phosphate buffer saline
- the isolated cells (3 ⁇ 10 6 cells / well) were seeded in 6-well plates, followed by 10% FBS (Fetal bovine serum, calf serum), 2 mM L-glutamine, 100 U / ml penicillin / streptomycin, 50 ⁇ M.
- Incubation and differentiation were initiated by addition of 1 ml RPMI 1640 comprising mercaptoethanol, 0.1 mM non-essential amino acid, 1 mM sodium pyruvate and 250 ng / ml FLT3L.
- Pam 3 was treated at a concentration of 100-500 ng / ml.
- 1 ml of RPMI 1640 was supplemented and incubated for 8 days.
- the cells obtained after the cultivation were subjected to plasmacytoid dendritic cells using a plasmacytoid dendritic cell separation kit (Miltenyi Biotec, Auburn, CA) and a magnetic cell sorting system (Vario MACS: Miltenyi Biotec, Auburn, CA). Separation (FIG. 2). Since the treatment of the toll-like receptor agonist may affect the differentiation of the plasmacytoid dendritic cells, the surface-expressing molecules specifically induced in the plasmacytoid dendritic cells are confirmed on the 8th day, and the results are shown in FIG. ).
- a plasmacytoid dendritic cell separation kit Miltenyi Biotec, Auburn, CA
- Vario MACS Miltenyi Biotec, Auburn, CA
- the toll-like receptor agonist when the toll-like receptor agonist was treated (TLRs-pDC), the ratio of the number of plasmacytoid dendritic cells obtained after 8 days to the number of initial immature dendritic cells was measured, and the result is shown in FIG. ).
- the case where the toll-like receptor agonist was not treated is shown as a comparative example (pDC).
- Example 2 In order to confirm the cytokine secretion of the plasma cytokine dendritic cells isolated in Example 1, inoculated cells (5 ⁇ 10 5 cells / ml) in 48 well plate and then ODN1826 (1 ⁇ g / ml) Treatment was stimulated. After 24 hours, the obtained supernatant was separated, and cytokine secretion was confirmed by an enzyme-linked immunosorbent assay (ELISA). The results are shown in FIG. 4. However, in order to confirm the treatment effect of the toll-like receptor agonist, the case where the toll-like receptor agonist was not treated during differentiation of immature dendritic cells in Example 1 is shown as a comparative example (pDC).
- pDC comparative example
- plasma-cytoid dendritic cells strongly induced type I interferons (IFN- ⁇ and IFN- ⁇ ) and representative inflammatory cytokines TNF- ⁇ and IL-12p70.
- toll-like receptor agonists 0.5 ⁇ g / ml
- TLRs-pDC differentiation-induced plasmacytoid dendritic cells
- ODN1826 ODN1826.
- IL-10 an immunosuppressive cytokine
- plasmacytoid dendritic cells induced by differentiation by treating a toll-like receptor agonist to immature dendritic cells according to the present invention were found to have immune tolerance unlike conventional plasmacytoid dendritic cells.
- plasmacytoid dendritic cells were induced in the same manner as in Example 1, but as the toll-like receptor agonist, ligands shown in Table 2 were used. After 8 days of incubation, plasmacytoid dendritic cells were separated with a purity of 85% or more using a plasmacytoid dendritic cell separation kit (Miltenyi Biotec, Auburn, CA) and a magnetic cell sorting system (Vario MACS: Miltenyi Biotec, Auburn, CA). It was.
- a plasmacytoid dendritic cell separation kit Miltenyi Biotec, Auburn, CA
- Vario MACS Miltenyi Biotec, Auburn, CA
- Isolated cells (5 ⁇ 10 5 cells / ml) were inoculated in 48 well plates, treated with ODN1826 (1 ⁇ g / ml) and incubated for 24 hours. Thereafter, only the supernatant was separated and the secretion pattern of the immunosuppressive cytokine IL-10 was confirmed by enzyme immunoassay. The results are shown in FIG. 5. However, in order to confirm the treatment effect of the toll-like receptor agonist, the case where the toll-like receptor agonist was not treated during differentiation of immature dendritic cells is shown as a comparative example (non).
- the differentiation of plasmacytoid dendritic cells is induced in the same manner as in Example 1, but the time to start the differentiation of the toll-like receptor agonist (0 day treatment)
- the treatment was performed after 3 days from the start of differentiation (3 day treatment).
- the plasmacytoid dendritic cells were purified to 85% or higher using a plasmacytoid dendritic cell separation kit (Miltenyi Biotec, Auburn, CA) and a magnetic cell sorting system (Vario MACS: Miltenyi Biotec, Auburn, CA). Separated.
- Isolated cells (5 ⁇ 10 5 cells / ml) were inoculated in 48 well plates, treated with ODN1826 (1 ⁇ g / ml) and incubated for 24 hours. After separating only the supernatant, the secretion pattern of cytokines was confirmed by enzyme immunoassay, and the results are shown in FIG. 6. However, in order to confirm the treatment effect of the toll-like receptor agonist, the case where the toll-like receptor agonist was not treated during the differentiation of immature dendritic cells is shown as a comparative example (no-treatment, non).
- the toll-like receptor agonist is treated at the start of differentiation of immature dendritic cells, that is, at the same time as FLT3L, a factor for inducing differentiation, the differentiation of immune tolerant plasmacytoid dendritic cells is induced as in the case of differentiation. there was.
- Dendritic cells including plasmacytoid dendritic cells, present antigens through MHC molecules to activate T cells upon recognition of foreign antigens and express co-stimulatory factors such as CD80 and CD86 to facilitate interaction.
- the plasmacytoid dendritic cells isolated in Example 1 were stimulated with ODN1826 and then cultured for 24 hours to confirm the expression level of the cell surface molecules.
- specific markers of plasmacytoid dendritic cells anti-CD11c (PE-Cy7, BD Biosciences), anti-PDCA-1 (PerCP-eFluor® 710 , ebioscience) and anti-CD80 (v450, BD Biosciences), anti-CD86 (APC, ebioscience), anti-MHC-I (PE, ebioscience) and anti-MHC-II (APC-eFluor) specific for cell surface molecules 780, ebioscience)
- the antibody was treated for 30 minutes at 4 ° C and analyzed by flow cytometry LSRFortessa x-20 (BD Biosciences). The results are shown in FIG. However, in order to confirm the treatment effect of the toll-like receptor agonist
- pDCs general plasmacytoid dendritic cells express high levels of co-stimulating factor CD86 and MHC class II molecules exogenous antigen presentation, but differentiation-induced plasma by treating toll-like receptor agonists Cytoid dendritic cells (TLRs-pDC) showed no or no response. Meanwhile, another co-stimulatory factor, CD80, and MHC class I molecules presenting endogenous or cross-antigens, were treated with toll-like receptor agonists and were not treated with differentiation-induced plasmacytoid dendritic cells (TLRs-pDC). It was confirmed that the expression at a higher level than (pDC).
- anti-CD11c PE-Cy7, BD Biosciences
- markers specific for plasmacytoid dendritic cells and Cell surface factor antibodies such as anti-PDCA-1 (PerCP-eFluor® 710, ebioscience) and immune tolerance induced cell surface molecules, such as anti-PD-L1 (PE, ebioscience) and anti-CCR9 (FITC, ebioscience)
- anti-PDCA-1 PerCP-eFluor® 710, ebioscience
- immune tolerance induced cell surface molecules such as anti-PD-L1 (PE, ebioscience) and anti-CCR9 (FITC, ebioscience
- CCR9 and IDO molecules were significantly increased compared to the untreated plasmacytoid dendritic cells upon stimulation with ODN1826.
- the expression of CCR9 was higher than that of untreated plasmacytoid dendritic cells even when unstimulated.
- TLRs-pDC differentiation-induced plasma cytokine dendritic cells
- RPMI1640 culture medium containing 10% FBS, 1% antibiotic and 100ng / ml of granulocyte-macrophage-colony stimulating factor (GM-CSF) was used for differentiation of dendritic cells. Incubated for 8 days. After 8 days of incubation, 5 ⁇ g / ml of Rv1411c protein was treated to wild-type dendritic cells (WT) and TLR2 knockout mice (TLR2-/-), respectively, and mixed for 2 hours intermittently. Facilitated. Then, the Hisv labeled with the Rv1411c protein was stained with an antibody having antigen-antibody specificity, and the degree of binding was measured using a flow cytometer. The results are shown in FIG. 10.
- wild-type dendritic cells showed increased binding to Rv1411c protein compared to TLR2 knockout dendritic cells (TLR2-/-), but in TLR2 knockout dendritic cells (TLR2-/-). Although the Rv1411c protein was treated, the same degree of binding as the untreated experimental group was confirmed.
- Example 8 Induced differentiation of immune tolerant plasmacytoid dendritic cells in the same process as in Example 1, but as the toll-like receptor agonist, the Rv1411c protein (0.1 ⁇ g / ml) was confirmed as a toll-like receptor agonist in Example 8. , 0.5 ⁇ g / ml) was used. After 8 days of incubation, plasmacytoid dendritic cells were separated with a purity of 85% or more using a plasmacytoid dendritic cell separation kit (Miltenyi Biotec, Auburn, CA) and a magnetic cell sorting system (Vario MACS: Miltenyi Biotec, Auburn, CA). It was.
- a plasmacytoid dendritic cell separation kit Miltenyi Biotec, Auburn, CA
- Isolated cells (5 ⁇ 10 5 cells / ml) were seeded in 48 well plates, treated with ODN1826 (1 ⁇ g / ml) and incubated for 24 hours. The supernatant obtained after the cultivation was isolated, and the results of confirming cytokine secretion by Enzyme Linked Immunosorbent assay (ELISA) are shown in a graph of FIG. 11. However, in order to confirm the treatment effect of Rv1411c protein, Rv1411c protein was untreated, and typical plasma cytoid dendritic cells stimulated (ODN +) or unstimulated (ODN ⁇ ) with ODN1826 are shown as comparative examples (pDC).
- ODN1826 Enzyme Linked Immunosorbent assay
- Rv1411c As shown in FIG. 11, stimulation of plasmacytoid dendritic cells (Rv1411c (0.1 ⁇ g / ml) -pDC, Rv1411c (0.5 ⁇ g / ml) -pDC) treated with Rv1411c protein with ODN1826 results in normal plasmacytoid dendritic cells.
- the concentrations of strongly induced type I interferons (IFN- ⁇ and IFN- ⁇ ) and the representative inflammatory cytokines TNF- ⁇ and IL-12p70 were rapidly reduced in a dose-dependent manner.
- IL-10 was found to increase its expression level in a concentration-dependent manner.
- the plasmacytoid dendritic cells treated with the Rv1411c protein were found to have immunotolerance differently from the normal plasmacytoid dendritic cells, and the degree of immune tolerance was also increased in proportion to the concentration of the Rv1411c protein. It was.
- Example 9 the expression patterns of surface molecules and enzymes in the plasmacytoid dendritic cells induced differentiation with Rv1411c protein were confirmed.
- markers specific for plasmacytoid dendritic cells include anti-CD11c (PE-Cy7, BD Biosciences) and anti-PDCA-1 (PerCP-eFluor 710, ebioscience ), Anti-CD80 (v450, BD Biosciences), anti-CD86 (APC, ebioscience), anti-MHC-I (PE, ebioscience) and anti-MHC-II (APC-eFluor® 780, ebioscience), anti-PD Cell surface factor antibodies such as -L1 (PE, ebioscience) and anti-CCR9 (FITC, ebioscience) were treated at 4 ° C.
- markers specific for plasmacytoid dendritic cells include anti-CD11c (PE-Cy7, BD Biosciences) and anti-PDCA-1 (PerCP-eFluor 710, ebioscience ), Anti-CD80 (v450, BD Biosciences), anti-CD86 (APC, ebioscience), anti-MHC
- the most important feature in vivo of immune tolerant plasmacytoid dendritic cells is to inhibit the activity of T lymphocytes.
- the following experiment was performed to determine the effect of differentiation-induced plasma cytokine dendritic cells on the proliferation and activity of T cells by treating Rv1411c protein in Example 9.
- T cells 1.5 ⁇ 10 5 cells / well isolated from allogeneic mice and stained with CellTrace (Invitrogen) were stimulated through 1 ⁇ PMA / Ionomycin (ebioscience). This treatment of PMA / Ionomycin increases the proliferation rate of T lymphocytes and promotes the secretion of interferon gamma (IFN-gamma).
- IFN-gamma interferon gamma
- the cells were treated with Tv and Rv1411c protein to induce differentiation-induced differentiation of plasmacytoid dendritic cells (Rv1411c-pDC) or general plasmacytoid dendritic cells (pDC) in a ratio of 1: 5 and incubated for 3 days. .
- Rv1411c protein was untreated, and typical plasma cytoid dendritic cells stimulated (ODN +) or unstimulated (ODN ⁇ ) with ODN1826 are shown as comparative examples (pDC).
- both plasmavoid dendritic cells (Rv1411c-pDC) and general plasmacytoid dendritic cells (pDC) induced by differentiation by treating Rv1411c protein induced T cell proliferation, but treated with Rv1411c protein to differentiate.
- the induced plasmacytoid dendritic cells (Rv1411c-pDC) were observed to have much lower proliferative induction capacity for CD4 + T cells than normal plasmacytoid dendritic cells (pDC).
- the secretion of IFN-gamma was lowered at a lower level than that of the non-treated plasmacytoid dendritic cells (pDCs) in which plasmavoid dendritic cells (Rv1411c-pDCs) induced by differentiation were treated with Rv1411c protein. It was confirmed to induce.
- pDCs plasmacytoid dendritic cells
- Rv1411c-pDCs plasmavoid dendritic cells
- T cells stained with CellTrace (Invitrogen) after isolation from allogeneic mice were treated with Rv1411c protein in Example 9 to induce differentiation of plasmacytoid dendritic cells (Rv1411c-pDC) or normal plasmacytoid dendritic cells (pDC). The ratio was 10: 1, 5: 1, or 1: 1 and incubated for 5 days. However, as the plasmacytoid dendritic cells were used ODN1826 stimulated (ODN +) and unstimulated (ODN-). Five days after incubation, cells were treated with anti-CD4 (Percp-cy5.5, ebioscience) for 30 minutes at 4 ° C. and Foxp3 / transcription factor staining buffer (ebioscience) at 37 ° C.
- T cells are reported to induce immune tolerant dendritic cells and inhibit the proliferation of other T cells. Therefore, below, according to Example 12, the activity of T cells induced by differentiation by Rv1411c protein as regulatory T cells was confirmed.
- mice spleens are isolated, red blood cells are removed, and CD4 + and CD25- activated T cells are isolated using a magnetic cell sorting system (MACS), and then stained with a violet proliferation dye to determine the extent of proliferation. It was. Differentiated T cells were then incubated for two days in wells coated with anti-CD3e and anti-CD28 antibodies with CD4 +, CD25- effector T cells. As a result, the change in T cell proliferative capacity was measured with respect to the ratio of primed T cells to CD25-acting T cells, and is graphically shown in FIG. 16.
- MCS magnetic cell sorting system
- Femoral bone marrow was harvested using bone marrow harvesting injections from C57BL / 6 mice. The collected bone marrow was washed with phosphate buffer saline (PBS) and red blood cells were removed using ammonium chloride. Isolated cells (5 ⁇ 10 5 cells / well) were seeded in 6-well plates, followed by 10% FBS (Fetal bovine serum, calf serum), 2 mM L-glutamine, 100 U / ml penicillin / streptomycin, 50 ⁇ M Incubation and differentiation were initiated by addition of 1 ml RPMI 1640 comprising mercaptoethanol, 0.1 mM non-essential amino acid, 1 mM sodium pyruvate and 250 ng / ml FLT3L.
- PBS phosphate buffer saline
- Rv1411c protein and Pam3 were treated with a toll like receptor agonist at a concentration of 100-500 ng / ml.
- 1 ml of RPMI 1640 was supplemented and incubated for 8 days.
- the cells obtained after the cultivation were subjected to plasmacytoid dendritic cells using a plasmacytoid dendritic cell separation kit (Miltenyi Biotec, Auburn, CA) and a magnetic cell sorting system (Vario MACS: Miltenyi Biotec, Auburn, CA). Separation.
- TLR agonist plasmacytoid dendritic cells
- mice generally known as collagen-induced arthritis disease animal models
- 100 ⁇ g bovine-derived type collagen in 0.05M acetic acid
- Freund's complete adjuvant Chondrex Inc., Redmod, Washington
- Example 9 After treating the Rv1411c protein in Example 9 to prepare differentiation-induced plasmacytoid dendritic cells and general plasmacytoid dendritic cells, 5 ⁇ g / ml type II collagen antigen and 1 ⁇ g / ml ODN1826 (TLR9 agonist) were prepared. After stimulation for 3 hours using the harvest (harvest). In order to confirm the therapeutic effect of arthritis due to the injection of the activated immune tolerant dendritic cells as described above, at the time of preparing the second emulsion as described above, plasma cytokines in both thighs of the prepared collagen-induced arthritis disease animal model mouse Droid Dendritic Cells 1 ⁇ 10 6 cells / mice were divided and injected by intramuscular injection (im).
- im intramuscular injection
- the severity of arthritis in each group was visually observed every 3 days and evaluated through the Arthritis score shown in Table 3 below, and each evaluator (3 persons) proceeded to the blindness evaluation and measured until 15 days after boosting. The results are shown graphically in FIG. 19. In addition, the incidence rate of arthritis in each group was measured and the results are shown in FIG. 20.
- collagen-induced arthritis animal model mice had no inhibitory effect of arthritis in the case of administering only a phosphorylated buffer aqueous solution (PBS) as a negative control (pBS) and injecting a common plasmacytoid dendritic cell (pDC).
- PBS phosphorylated buffer aqueous solution
- pDC plasmacytoid dendritic cell
- TLRs-tolpDC differentiation-induced immune tolerant plasmacytoid dendritic cells
- Rv1411c protein treatment inhibited arthritis symptoms by about 86% compared to the negative control group. It was confirmed that the arthritis inhibitory effect was superior to that of the known methotrexate administered (MTX).
- the differentiation-induced immune tolerant plasmacytoid cells according to the present invention inhibit the induction of arthritis and alleviate the symptoms.
- a collagen-induced arthritis animal model was prepared in the same manner as in Example 15, followed by treatment with phosphorylated buffered aqueous solution (PBS) as a negative control, methotrexate (MTX) as a positive control, or Rv1411c protein in Example 9 to induce differentiation.
- PBS phosphorylated buffered aqueous solution
- MTX methotrexate
- Rv1411c protein Rv1411c protein
- mice The hind paws of each of the treated collagen-induced arthritis animal model mice were fixed with 4 to 4% paraformaldehyde for 6 days and then demineralized with aqueous ammonia solution (2.52% NH4OH, 14% EDTA-acid) for 4 days. .
- Tissues were paraffinized and sections were sliced through slitting and stained with hematoxylin and eosin. The photos of the stained tissue are shown in FIG. 21.
- the severity of arthritis symptoms in the slide results of the stained tissue was quantitatively scored according to the criteria of Table 4 below, and the results are shown in FIG. 22.
- collagen-induced arthritis animal model mice treated with immune tolerant plasmacytoid dendritic cells induced differentiation through Rv1411c protein treatment as compared to the case of administering only a phosphorylated buffer aqueous solution as a negative control (PBS) (TLRs-pDC) is a pathology in joint tissues caused by inflammation, as well as external suppressive effects due to disease, through relatively large reductions in the infiltration of immune cells in the joints, destruction of cartilage tissues, and bone corrosion in the joint tissues of mice. The mitigative effect was confirmed.
- TLRs-pDC plasmacytoid dendritic cells
- PBS phosphorylated buffered aqueous solution
- differentiation-induced immune tolerant plasmacytoid cells alleviate the symptoms of arthritis and further have a therapeutic effect.
- a collagen-induced arthritis animal model was prepared in the same manner as in Example 15, followed by treatment with phosphorylated buffered aqueous solution (PBS) as a negative control, methotrexate (MTX) as a positive control, or Rv1411c protein in Example 9 to induce differentiation.
- PBS phosphorylated buffered aqueous solution
- MTX methotrexate
- Rv1411c protein Rv1411c protein in Example 9
- TLRs-pDC tumor necrosis factor- ⁇
- IL-6 interleukin-6
- IL-17 interleukin-17
- TNF- ⁇ As shown in FIG. 23, in the negative control group (PBS) administered only the phosphorylated buffer aqueous solution compared to the normal group, the concentrations of the inflammatory cytokines TNF- ⁇ , IL-6 and IL-17 were significantly increased. there was. However, in the case of administration of differentiation-induced immune tolerant plasmacytoid dendritic cells (TLRs-pDC) through Rv1411c protein treatment, TNF- ⁇ was about 48%, IL-6 was about 47%, IL-6 compared to the negative control (PBS). -17 was found to significantly reduce the expression level of about 37%.
- TLRs-pDC differentiation-induced immune tolerant plasmacytoid dendritic cells
- differentiation-induced immune tolerant plasmacytoid cells according to the present invention was confirmed to have an effect of alleviating arthritis diseases by inhibiting the production of inflammatory cytokines.
- each specific primer RT-PCR was performed.
- a collagen-induced arthritis animal model was prepared in the same manner as in Example 15, and then differentiated by treating phosphorylated buffered aqueous solution (PBS) as a negative control, methotrexate (MTX) as a positive control, or Rv1411c protein in Example 9 above.
- PBS phosphorylated buffered aqueous solution
- MTX methotrexate
- Rv1411c protein Rv1411c protein
- the main proinflammatory factor parameters are the representative inflammatory cytokines IL-1 ⁇ and IL-6, inflammatory chemokines MCP-1 (CCL2), MIP-1 (CCL3) and RANTES (CCL5), and inflammatory matrix proteins involved in bone joint destruction.
- IL-1 ⁇ and IL-6 inflammatory chemokines
- MCP-1 CCL2
- MIP-1 CCL3
- RANTES CTL5
- inflammatory matrix proteins involved in bone joint destruction corresponds to the matrix metalloproteinase MMP-1 (collagenase).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
리간드 | PAMPs(Pathogen Associated Ligands) | 리간드 유래 호스트(Ligand natural host) | 합성 리간드 |
TLR1 | 다양한 트리아실 리포펩티드(multiple triacyl lipopeptides) | 박테리아 | Pam3Cys-* |
TLR2 | 다양한 글리코리피드(multiple glycolipids) | 박테리아 | CFA |
다양한 리포펩티드(multiple lipopeptides) | 박테리아 | Pam3, MALP2-** | |
다양한 리포프로테인(multiple lipoproteins) | 박테리아 | Pam2Cys** | |
리포테이코산(lipoteichoic acid) | 그람 양성 박테리아 | FSL-1 | |
HSP 70, 또는 다른 열 충격 단백질(other heat shock proteins) | 숙주 세포(host cells) | Hib-OMPC | |
지모산(zymosan) (Beta- glucan) | 균류 (fungi) | ||
단백질 | 결핵균(Mycobacterium tuberculosis) | Rv1411c 단백질, ESAT-6, PE/PPE Protein, Rv0577 | |
TLR3 | 이중 가닥 RNA(double stranded RNA) | 바이러스 | Poly (I: C); 저분자량 또는 고분자량Poly (A: U) |
TLR4 | 리포다당류(lipopolysaccharides, LPS); or IPS 유사체(MPLA) | 그람 음성 박테리아 | AGP |
열 충격 단백질 | 박테리아 및 숙주 세포 | MPLA | |
피브리노겐(fibrinogen) | 숙주 세포 | RC-529 | |
헤파린 황산 프레그먼트(heparin sulfate fragments) | 숙주 세포 | MDF2B | |
히알루론산 프레그먼트(hyaluronic acid fragments) | 숙주 세포 | CFA | |
니켈(nickel) | |||
다양한 오피오이드 약제(Various opoid drugs) | |||
단백질 | 결핵균(Mycobacterium tuberculosis) | RpfE, RpfB, Rv2299c, HBHA | |
TLR5 | 플라젤린(Flagellin) | 박테리아 | 플라젤린 |
TLR6 | 다양한 디아실 리포펩티드(multiple diacyl lipopeptides) | 마이코플라즈마(mycoplasma) | FSL1-**Pam2Cys**MALP2-** |
TLR7 | 바이러스 ssRNA(인플루엔자, VSV, HIV, HCV) | RNA 바이러스 | 구아노신 아날로그(guanosine analogs);이미다조퀴놀린(imidazoquinolines)(e.g. 이미퀴모드(Imiquimod), Aldara R848, 레시퀴모드(Resiquimod) ), 록소리빈(loxoribine) |
TLR8 | 작은 합성 화합물(small synthetic compounds); 단일 가닥 RNA(single-stranded RNA) | RNA, 인간 및 바이러스 | 이미다조퀴놀린;록소리빈;ssPolyU, 3M-012 |
TLR9 | 비메틸화된 CpG 올리고뉴클레오티드 DNA(Unmethylated CpG Oligodeoxynucleotide DNA); DNA; dsDNA 바이러스(HSV, MCMV); 헤모조인(Hemozoin)(Plasmodium) | 박테리아, DNA 바이러스 | CpG-올리고뉴클레오티드, 합성된 다양한 서열들(e.g. CpG-ODN 2006, 1826, 2395) |
TLR10 | |||
TLR11 | 프로필린(Profilin) | 톡소플라즈마 곤디(Toxoplasma gondii) | |
TLR12 | 프로필린(Profilin) | 톡소플라즈마 곤디(Toxoplasma gondii) | |
TLR13 | 박테리아 리보솜 RNA 서열(bacterial ribosomal RNA sequence)"CGGAAAGACC" | 바이러스, 박테리아 | |
* TLR1 및 TLR2에 의해 인식되는 리간드** TLR2 및 TLR6에 의해 인식되는 리간드 |
Non | TLR2 작용제 | TLR3 작용제 | TLR4 작용제 | TLR7 작용제 | TLR9 작용제 |
미처리 | Pam3 | Poly I:C | LPS | 이미퀴모드 | CpG-ODN |
질환 점수 | 관절염 증상 |
0 | 부종이나 종장이 없다. |
1 | 발 또는 발목관절에 국한된 경한 부종과 발적 |
2 | 발목관절에서 족근골(metatarsal)에 걸친 경한 부종과 발적 |
3 | 발목관절에서 족근골에 걸친 중등도의 부종과 발적 |
4 | 발목에서 다리전체에 걸쳐 부종과 발적이 있는 경우 |
질환 점수 | 증상 |
0 | 정상 |
1 | 염증 세포의 침윤(infiltration of inflammatory cells) |
2 | 약한 염증 및 판누스(pannus) 형성 |
3 | 중증 염증 및 판누스(pannus) 형성 |
4 | 두드러진 침윤 |
5 | 심각한 침윤 및 심각한 확산 연골(diffuse cartilage) |
구분 | 프라이머 | 유전자 |
1 | Forward 5-ATGGCAACTGTTCCTGAACTCAAC-3 | 마우스 IL-1β |
2 | Reverse 5-CAGGACAGGTATAGATTCTTTCCTTT-3 | |
3 | Forward 5-ATGAAGTTCCTCTCTGCAAGAGACT-3 | 마우스 IL-6 |
4 | Reverse 5-CACTAGGTTTGCCGAGTAGATCTC-3 | |
5 | Forward 5-TCCACCACCATGCAGGTCCC-3 | 마우스 MCP-1 |
6 | Reverse 5-CAGCAGGTGAGTGGGGCGTT-3 | |
7 | Forward 5-CCTCTTGCTCGTGGCTGCCT-3 | 마우스 MIP-1 |
8 | Reverse 5-AGTGGCTCCTCCTGCCCTGC-3 | |
9 | Forward 5-CCTCACCATCATCCTCACTGCA-3 | 마우스 RANTES |
10 | Reverse 5-TCTTCTCTGGGTTGGCACACAC-3 | |
11 | Forward 5-CCAGGTGTGGGGTGCCTGAT-3 | 마우스 MMP-1 |
12 | Reverse 5-CAAACCTGGGCCTGGCTGGA-3 | |
13 | Forward 5-GAAGGTGAAGGTCGGAGT-3 | 마우스 GAPDH |
14 | Reverse 5-GAAGATGGTGATGGGATTTC-3 |
Claims (21)
- 미성숙 수지상 세포에 톨 유사 수용체 작용제(toll-like receptor agonist)를 처리하여 면역 관용성 플라즈마사이토이드 수지상 세포(plasmacytoid dendritic cells, pDC)를 제조하는 단계를 포함하는, 자가 면역 질환의 예방 또는 치료용 약학적 조성물의 제조방법.
- 제1항에 있어서,상기 톨 유사 수용체 작용제는 상기 미성숙 수지상 세포의 분화 개시 이전 또는 분화 중에 처리되어, 면역 관용성 플라즈마사이토이드 수지상 세포로의 분화를 유도하는, 자가 면역 질환의 예방 또는 치료용 약학적 조성물의 제조방법.
- 제1항에 있어서,상기 톨 유사 수용체 작용제는 상기 미성숙 수지상 세포의 분화 개시 시점으로부터 분화 완료 이전에 처리되는, 자가 면역 질환의 예방 또는 치료용 약학적 조성물의 제조방법.
- 제2항 또는 제3항에 있어서,상기 미성숙 수지상 세포의 분화는 분화 유도용 인자를 사용하여 수행되는, 자가 면역 질환의 예방 또는 치료용 약학적 조성물의 제조방법.
- 제4항에 있어서,상기 분화 유도용 인자는 FMS-유사 티로신 키네이즈 3 리간드(FMS-like tyrosine kinase 3, Flt3L)인, 자가 면역 질환의 예방 또는 치료용 약학적 조성물의 제조방법.
- 제4항에 있어서,상기 분화 유도용 인자는 상기 미성숙 수지상 세포에 1회 이상 처리되는, 자가 면역 질환의 예방 또는 치료용 약학적 조성물의 제조방법.
- 제1항에 있어서,상기 톨 유사 수용체 작용제는 상기 분화 유도용 인자와 동시에 상기 미성숙 수지상 세포에 처리되는, 자가 면역 질환의 예방 또는 치료용 약학적 조성물의 제조방법.
- 제1항에 있어서,상기 톨 유사 수용체 작용제는 1회 이상 처리되는, 자가 면역 질환의 예방 또는 치료용 약학적 조성물의 제조방법.
- 제1항에 있어서,상기 톨 유사 수용체 작용제는 MyD88(Myeloid differentiation primary response gene 88) 시그널을 경유하는 것인, 자가 면역 질환의 예방 또는 치료용 약학적 조성물의 제조방법.
- 제1항에 있어서,상기 톨 유사 수용체 작용제는 TLR2 작용제, TLR4 작용제, TLR5 작용제, TLR7 작용제, TLR8 작용제, TLR9 작용제, TLR11 작용제, TLR12 작용제 및 TLR13 작용제로 이루어진 군에서 선택된 1종 이상을 포함하는, 자가 면역 질환의 예방 또는 치료용 약학적 조성물의 제조방법.
- 제10항에 있어서,상기 톨 유사 수용체 작용제는 TLR1 작용제 및 TLR6 작용제 중 적어도 하나를 추가로 더 포함하는, 자가 면역 질환의 예방 또는 치료용 약학적 조성물의 제조방법.
- 제2항에 있어서,상기 분화 유도된 면역 관용성 플라즈마사이토이드 수지상 세포에 톨 유사 수용체 작용제를 추가로 처리하여 면역 관용성을 활성화시키는 단계를 더 포함하는, 자가 면역 질환의 예방 또는 치료용 약학적 조성물의 제조방법.
- 제12항에 있어서,상기 면역 관용성을 활성화시키기 위하여 사용되는 상기 톨 유사 수용체 작용제는 TLR9 작용제인, 자가 면역 질환의 예방 또는 치료용 약학적 조성물의 제조방법.
- 제1항에 있어서,상기 자가 면역 질환은 류마티스 관절염, 전신성 홍반성 루푸스, 패혈증성 쇼크, 알러지성 천식, 알러지성 비염, 아토피성 피부염, 궤양성 대장염, 누선염, 알츠하이머 질환, 뇌졸중, 동맥경화증, 혈관 재협착, I형 당뇨병, II형 당뇨병, 담마진, 결막염, 건선, 전신성염증반증후군, 다발성근염, 피부근염, 결절성 다발관절염, 혼합결합 조직증, 쉐그렌증후군, 통풍, 파킨슨병, 근위축성측색경화증, 당뇨성망막증, 다발성경화증, 크론병, 만성 갑상선염, 세리아크병, 중증근무력증, 심상성천포창, 바이러스질환, 세균성질환, 방사선에 의한 장해, 동맥경화, 혈관종, 혈관섬유종, 재관류장해 및 심장비대증으로 이루어진 군에서 선택된 1종 이상인, 자가 면역 질환의 예방 또는 치료용 약학적 조성물의 제조방법.
- 미성숙 수지상 세포에 톨 유사 수용체 작용제를 처리하여 유도된 면역 관용성 플라즈마사이토이드 수지상 세포를 포함하는, 자가 면역 질환의 예방 또는 치료용 약학적 조성물.
- 제15항에 있어서,상기 면역 관용성 플라즈마사이토이드 수지상 세포는, 상기 미성숙 수지상 세포의 분화 개시 이전 또는 분화 중에 상기 톨 유사 수용체 작용제가 처리되어 분화 유도된 것인, 자가 면역 질환의 예방 또는 치료용 약학적 조성물.
- 제15항에 있어서,상기 톨 유사 수용체 작용제는 TLR2 작용제, TLR4 작용제, TLR5 작용제, TLR7 작용제, TLR8 작용제, TLR9 작용제, TLR11 작용제, TLR12 작용제 및 TLR13 작용제로 이루어진 군에서 선택된 1종 이상을 포함하는, 자가 면역 질환의 예방 또는 치료용 약학적 조성물.
- 제17항에 있어서,상기 톨 유사 수용체 작용제는 TLR1 작용제 및 TLR6 작용제 중 적어도 하나를 추가로 더 포함하는, 자가 면역 질환의 예방 또는 치료용 약학적 조성물.
- 제15항에 있어서,상기 자가 면역 질환은 류마티스 관절염, 전신성 홍반성 루푸스, 패혈증성 쇼크, 알러지성 천식, 알러지성 비염, 아토피성 피부염, 궤양성 대장염, 누선염, 알츠하이머 질환, 뇌졸중, 동맥경화증, 혈관 재협착, I형 당뇨병, II형 당뇨병, 담마진, 결막염, 건선, 전신성염증반증후군, 다발성근염, 피부근염, 결절성 다발관절염, 혼합결합 조직증, 쉐그렌증후군, 통풍, 파킨슨병, 근위축성측색경화증, 당뇨성망막증, 다발성경화증, 크론병, 만성 갑상선염, 세리아크병, 중증근무력증, 심상성천포창, 바이러스질환, 세균성질환, 방사선에 의한 장해, 동맥경화, 혈관종, 혈관섬유종, 재관류장해 및 심장비대증으로 이루어진 군에서 선택된 1종 이상인, 자가 면역 질환의 예방 또는 치료용 약학적 조성물.
- 미성숙 수지상 세포에 톨 유사 수용체 작용제를 처리하여 유도된 면역 관용성 플라즈마사이토이드 수지상 세포를 포함하는, 자가 면역 질환의 예방 또는 개선용 화장료 조성물.
- 미성숙 수지상 세포에 톨 유사 수용체 작용제를 처리하여 유도된 면역 관용성 플라즈마사이토이드 수지상 세포를 포함하는, 자가 면역 질환의 예방 또는 개선용 식품 조성물.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880009549.3A CN110337298A (zh) | 2017-01-31 | 2018-01-30 | 用于预防或治疗自身免疫疾病的药学组合物及其制备方法 |
US16/482,096 US20200246380A1 (en) | 2017-01-31 | 2018-01-30 | Pharmaceutical Composition for Preventing or Treating Autoimmune Disease, and Method for Producing Same |
BR112019015783-2A BR112019015783A2 (pt) | 2017-01-31 | 2018-01-30 | Composição farmaceutica para prevenção ou tratamento de doença autoimune e método para a produção da mesma |
CA3052130A CA3052130A1 (en) | 2017-01-31 | 2018-01-30 | Pharmaceutical composition for preventing or treating autoimmune disease, and method for producing same |
EP18747981.1A EP3578186A4 (en) | 2017-01-31 | 2018-01-30 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AUTOIMMUNE DISEASE, AND PROCESS FOR PRODUCTION |
AU2018215650A AU2018215650A1 (en) | 2017-01-31 | 2018-01-30 | Pharmaceutical composition for preventing or treating autoimmune disease, and method for producing same |
JP2019541263A JP2020506186A (ja) | 2017-01-31 | 2018-01-30 | 自己免疫疾患の予防または治療用薬学的組成物およびその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0014074 | 2017-01-31 | ||
KR1020170014074A KR101893886B1 (ko) | 2017-01-31 | 2017-01-31 | 자가 면역 질환의 예방 또는 치료용 약학적 조성물 및 그 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018143649A1 true WO2018143649A1 (ko) | 2018-08-09 |
Family
ID=63040139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/001294 WO2018143649A1 (ko) | 2017-01-31 | 2018-01-30 | 자가 면역 질환의 예방 또는 치료용 약학적 조성물 및 그 제조방법 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200246380A1 (ko) |
EP (1) | EP3578186A4 (ko) |
JP (1) | JP2020506186A (ko) |
KR (1) | KR101893886B1 (ko) |
CN (1) | CN110337298A (ko) |
AU (1) | AU2018215650A1 (ko) |
BR (1) | BR112019015783A2 (ko) |
CA (1) | CA3052130A1 (ko) |
WO (1) | WO2018143649A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230015715A (ko) * | 2021-07-23 | 2023-01-31 | 주식회사 파로스백신 | Clec5a 발현 면역관용 수지상세포 또는 그의 배양물을 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030133913A1 (en) * | 2001-08-30 | 2003-07-17 | 3M Innovative Properties Company | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
US20100080816A1 (en) * | 2008-09-25 | 2010-04-01 | Husein Hadeiba | Tolerogenic populations of dendritic cells |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1674479A1 (en) * | 2004-12-22 | 2006-06-28 | Memorial Sloan-Kettering Cancer Center | Modulation of Fc Gamma receptors for optimizing immunotherapy |
WO2012158556A1 (en) * | 2011-05-13 | 2012-11-22 | University Of Southern California | Tolerogenic plasmacytoid dendritic cells co-expressing cd8-alpha and cd8-beta and methods of inducing the differentiation of regulatory t cells using same |
-
2017
- 2017-01-31 KR KR1020170014074A patent/KR101893886B1/ko active IP Right Grant
-
2018
- 2018-01-30 CN CN201880009549.3A patent/CN110337298A/zh active Pending
- 2018-01-30 US US16/482,096 patent/US20200246380A1/en not_active Abandoned
- 2018-01-30 WO PCT/KR2018/001294 patent/WO2018143649A1/ko unknown
- 2018-01-30 EP EP18747981.1A patent/EP3578186A4/en not_active Withdrawn
- 2018-01-30 JP JP2019541263A patent/JP2020506186A/ja active Pending
- 2018-01-30 BR BR112019015783-2A patent/BR112019015783A2/pt not_active IP Right Cessation
- 2018-01-30 CA CA3052130A patent/CA3052130A1/en not_active Abandoned
- 2018-01-30 AU AU2018215650A patent/AU2018215650A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030133913A1 (en) * | 2001-08-30 | 2003-07-17 | 3M Innovative Properties Company | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
US20100080816A1 (en) * | 2008-09-25 | 2010-04-01 | Husein Hadeiba | Tolerogenic populations of dendritic cells |
Non-Patent Citations (4)
Title |
---|
CHAMORRO, S.: "TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program", THE JOURNAL OF IMMUNOLOGY, vol. 183, 2009, pages 2984 - 2994, XP055530573 * |
MITCHELL, D.: "Dual stimulation of MyD88-dependent Toll-like receptors induces synergistically enhanced production of inflammatory cytokines in murine bone marrow-derived dendritic cells", THE JOURNAL OF INFECTIOUS, vol. 202, no. 2, 15 July 2010 (2010-07-15), pages 318 - 329, XP05530580 * |
REIZIS, B.: "Plasmacytoid dendritic cells: recent progress and open questions", ANNUAL REVIEW OF IMMUNOLOGY, vol. 39, no. 1, 5 January 2011 (2011-01-05), pages 163 - 183, XP055082976 * |
See also references of EP3578186A4 * |
Also Published As
Publication number | Publication date |
---|---|
CN110337298A (zh) | 2019-10-15 |
CA3052130A1 (en) | 2018-08-09 |
KR20180089223A (ko) | 2018-08-08 |
BR112019015783A2 (pt) | 2020-03-17 |
AU2018215650A1 (en) | 2019-08-22 |
US20200246380A1 (en) | 2020-08-06 |
EP3578186A4 (en) | 2020-12-09 |
JP2020506186A (ja) | 2020-02-27 |
KR101893886B1 (ko) | 2018-08-31 |
EP3578186A1 (en) | 2019-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012026712A4 (ko) | Nod2의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물 | |
WO2018097540A9 (ko) | 무혈청면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물 | |
WO2016048107A1 (ko) | 인터페론-감마 또는 인터류킨-1베타를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물 | |
WO2013129739A1 (ko) | 봉독-pla2를 포함하는 이상 조절 t 세포 활성 저하 관련 질환의 치료 또는 예방용 약학적 조성물 | |
WO2017146538A1 (ko) | 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2018143649A1 (ko) | 자가 면역 질환의 예방 또는 치료용 약학적 조성물 및 그 제조방법 | |
WO2019216623A1 (ko) | 당뇨병 및 비만 치료용 면역관용 세포 백신 및 인슐린 분비 세포의 제조 방법 | |
Li et al. | Cholecystokinin octapeptide significantly suppresses collagen-induced arthritis in mice by inhibiting Th17 polarization primed by dendritic cells | |
WO2018143650A1 (ko) | 과민성 면역 질환의 예방 또는 치료용 약학적 조성물 및 그 제조방법 | |
WO2019027214A9 (ko) | 동종-중간엽 줄기세포 및 이의 용도 | |
WO2018143652A1 (ko) | 면역 관용성 플라즈마사이토이드 수지상 세포 및 그 제조방법 | |
WO2022108306A1 (ko) | 인터류킨-33을 처리하여 면역원성이 향상된 cd103+ fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물 | |
WO2015023147A1 (ko) | mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽 줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
WO2015023165A1 (ko) | 염증조절복합체 및 stat3 신호분자 차단을 통한 면역조절능 최적화된 안정화 중간엽줄기세포 | |
WO2022250416A1 (ko) | 리포펩타이드와 폴리(i:c) 아쥬번트를 이용하는 면역항암치료제 조성물 | |
WO2022139524A1 (ko) | 신규 fk506 유도체 및 이를 포함하는 발모 촉진용 조성물 | |
WO2021251790A1 (ko) | 항비만 활성을 가지는 디옥시콜산-펩타이드 결합체 및 이의 용도 | |
WO2019066571A2 (ko) | 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도 | |
WO2015194710A1 (ko) | Stat3 억제제가 처리된 간엽줄기세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
KR102003958B1 (ko) | 과민성 면역 질환의 예방 또는 치료용 약학적 조성물 및 그 제조방법 | |
WO2019212123A1 (ko) | 수지상세포의 이동능을 증가시키는 방법 및 이의 용도 | |
WO2023003406A1 (ko) | Clec5a 발현 면역관용 수지상세포 또는 그의 배양물을 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 | |
WO2017213407A1 (ko) | Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물 | |
WO2024143863A1 (ko) | 인터류킨-33로 활성화된 인접면역세포 매개 면역원성 향상 수지상 세포의 배양방법 및 상기 수지상 세포를 이용하여 세포독성 t 세포를 활성화하는 방법. | |
WO2024151124A1 (ko) | 항암능이 우수한 기억 t 세포 유래 면역세포치료제의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18747981 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3052130 Country of ref document: CA Ref document number: 2019541263 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019015783 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2018215650 Country of ref document: AU Date of ref document: 20180130 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018747981 Country of ref document: EP Effective date: 20190902 |
|
ENP | Entry into the national phase |
Ref document number: 112019015783 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190731 |